|
|
|
| The Curative Effect Study of Continous Hyperthermic Peritoneal Perfusion Chemotherapy with Lobaplatin Combined with Intravenous Chemotherapy in the Treatment of Advanced Ovary Cancer |
| The First Affiliated Hospital South China University，Hengyang 421001，China |
|
|
|
|
Abstract Objective：To explore curative effect and side effects of the patients with ovarian epithelial cell carcinoma after surgery administered by continous hyperthermic peritoneal perfusion chemotherapy（ CHPPC） with lobaplatin in combination with intravenous chemotherapy（IC）.Method：46 cases of advanced ovarian carcinoma patients after cytoreductive or radical surgery were selected from July 2007 to July 2009，and were divided into cisplatin group and the Lobaplatin group，23 cases in each group，all of them were treated IC+CHPPC， curative effect and side effects were observed.Result：The 46 patients of two groups finished all six cycles chemotherapy.In Lobaplatin group three-year and five-year survival rates respectively was 69.5%，52.1%，the differences were not statistically significant（P>0.05）.Although we find the two groups had statistically significant in some aspects（P<0.05）， all the patients could stand them.Conclusion：Continous hyperthermic peritoneal perfusion chemotherapy with Lobaplatin in combination with intravenous chemotherapy are safe and feasible treatment modality for patients with advanced ovary carcinoma.Patients in lobaplatin group have better compliance than cisplatin， but the two medicines both have acceptable complications rates，all have marked improvements in survival.
|
|
|
|
|
|
|
|
|
